G. Eckhardt

发表

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

J. Heymach, P. LoRusso, A. Patnaik, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.

E. Raymond, D. V. Von Hoff, G. Clark, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.

R. Herbst, R. Kurzrock, W. Novotny, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors

R. Herbst, D. Branstetter, G. Eckhardt, 2007 .

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

A. Tolcher, T. Whiteside, J. Stephenson, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

New anticancer agents in clinical development.

D. V. Von Hoff, M. Villalona-Calero, G. Eckhardt, 1995, Oncology.

New anticancer agents in clinical development.

D. V. Von Hoff, M. Villalona-Calero, G. Eckhardt, 1995, Oncology.

A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer.

R. Camidge, C. Britten, S. Leong, 2006, Journal of Clinical Oncology.

Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

Peter G. Smith, J. Tentler, G. Eckhardt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

L. Ellis, M. Korc, J. Berlin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer

E. Giovannetti, G. Tortora, D. Raben, 2006, Clinical Cancer Research.

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

M. Gulley, D. V. Von Hoff, I. Ganly, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ephrin‐B2 overexpression predicts for poor prognosis and response to therapy in solid tumors

A. Jimeno, S. Karam, J. Califano, 2017, Molecular carcinogenesis.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

A. Jimeno, M. Varella‐Garcia, D. Gao, 2016, International journal of cancer.

Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

C. Atreya, A. Tan, R. Kelley, 2015, International journal of cancer.

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Jing Wang, J. Lee, A. Futreal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers

J. Verweij, Honghui Zhou, R. Capdeville, 2000, Journal of clinical pharmacology.

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

C. Korch, F. Hirsch, M. Varella‐Garcia, 2010, Clinical Cancer Research.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer

H. Selby, A. Tan, S. Eckhardt, 2016, Oncotarget.

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

C. Korch, S. Leong, J. Tentler, 2010, Clinical Cancer Research.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

A. Jimeno, D. Gao, S. Kopetz, 2016, International journal of cancer.

Abstract B238: A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma

A. Jimeno, R. Camidge, S. Leong, 2009 .